Minerva Neurosciences (NERV) Change in Cash (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Change in Cash data on file, last reported at -$49.6 million in Q1 2026.

• Quarterly Change in Cash fell 1119.12% year-over-year to -$49.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.4 million (up 187.69% YoY) and the FY2025 annual result came in at $60.9 million, up 411.7% from the prior year.
• Change in Cash fell to -$49.6 million in Q1 2026, from $70.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $70.0 million in Q4 2025 to a low of -$49.6 million in Q1 2026.
• A 5-year average of -$1.7 million and a median of -$4.4 million in 2024 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2024 — Change in Cash slumped 5180.68% — and 2025, when it soared 1455.1%.
• Tracing NERV's Change in Cash over 5 years: stood at -$4.1 million in 2022, then tumbled by 45.2% to -$6.0 million in 2023, then grew by 13.76% to -$5.2 million in 2024, then soared by 1455.1% to $70.0 million in 2025, then plunged by 170.9% to -$49.6 million in 2026.
• The last three Change in Cash figures came in at -$49.6 million (Q1 2026), $70.0 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.